News
DMX-200 is a small molecule inhibitor of the chemokine receptor 2 (CCR2) under development in a pivotal Phase 3 study, ACTION3, for the treatment of Focal Segmental Glomerulosclerosis (FSGS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback